Status:
RECRUITING
Screening for Oculocerebral Lymphoma with the Phenotype of NK Cells in Patients with Uveitis
Lead Sponsor:
Hospices Civils de Lyon
Conditions:
Uveitis
Lymphoma
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Uveitis is an inflammation of the uvea, an ocular tunic comprising the iris, ciliary body and choroid. This inflammation can also involve other tissues such as the retina, the optic nerve and the aque...
Eligibility Criteria
Inclusion
- GENERAL CRITERIA
- Male or female over 18 years of age,
- Free, informed, written consent signed by the patient and the investigator (at the latest on the day of inclusion) and before any examination required by the research,
- Patient affiliated to the social security system or beneficiary of such a system,
- Maximum volume of sampling (care + research) per 30-day period to be adapted according to the patient's weight (Order of April 12, 2018 establishing the list of research mentioned in 2° of Article L. 1121-1).
- SPECIFIC CRITERIA
- \- Patient affected in one or both eyes: of uveitis with another diagnosis than ocular lymphoma and without cerebral lymphoma (Group 1), or primary ocular lymphoma without brain involvement and never treated (Group 2), or primary ocular lymphoma without brain involvement, treated and considered in remission (IL10 HA level \< 10) (Group 3), or primary ocular lymphoma without brain involvement, and considered in relapse (IL10 HA level \> 30) (Group 4), or cerebral lymphoma with or without ocular involvement and without uveitis (Group 5), or cataract (pre- and post-op), glaucoma, retinal detachment or epiretinal retinal detachment or epiretinal membrane, but no brain damage or uveitis (group 6).
Exclusion
- -GENERAL CRITERIA
- Patient participating in an ongoing clinical trial at the time of the inclusion visit,
- Pregnant women, women in labor or nursing mothers,
- Persons deprived of liberty by a judicial or administrative decision,
- Persons under psychiatric care,
- Persons admitted to a health or social institution for purposes other than research,
- Persons of full age who are subject to a legal protection measure (guardianship, curatorship).
- SPECIFIC CRITERIA
- Patient for whom the diagnosis of ocular or cerebral lymphoma is uncertain,
- Patient with another systemic cancer that is evolving or in remission \< 2 years.
Key Trial Info
Start Date :
June 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2025
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT05388838
Start Date
June 1 2022
End Date
December 1 2025
Last Update
March 3 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Service d'Ophtalmologie, Hôpital de la Croix-Rousse, GHN
Lyon, France, 69004
2
Service d'Hématologie Clinique, Hôpital Lyon Sud
Lyon, France, 69310